Budesonide
- Generic Name
- Budesonide
- Brand Names
- Airsupra, Breyna, Breztri, Cortiment, Entocort, Pulmicort, Pulmicort Turbuhaler, Rhinocort, Symbicort, Tarpeyo, Uceris, Jorveza, Kinpeygo
- Drug Type
- Small Molecule
- Chemical Formula
- C25H34O6
- CAS Number
- 51333-22-3
- Unique Ingredient Identifier
- Q3OKS62Q6X
- Background
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with formoterol.
- Indication
Budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate Crohn’s disease. Various inhaled budesonide products are indicated for prophylactic therapy in asthma and to reduce exacerbations of COPD. A budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergies. E...
- Associated Conditions
- Allergic Reaction, Allergic Rhinitis (AR), Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Collagenous Colitis, Crohn's Disease (CD), Eosinophilic Esophagitis, Exacerbation of asthma, Nasal Congestion, Nasal Polyps, Proteinuria, Pruritus, Rhino Sinusitis, Ulcerative Colitis, Vasomotor Rhinitis, Corticosteroid-responsive dermatoses, Mild Crohn’s Disease, Moderate Crohn’s Disease
- Associated Therapies
- Maintenance therapy
Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans
- Conditions
- Interventions
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2012-11-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 311
- Registration Number
- NCT00702325
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
CARE Network Maintenance Versus Intermittent Inhaled Steroids in Wheezing Toddlers (MIST)
- First Posted Date
- 2008-05-09
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 278
- Registration Number
- NCT00675584
- Locations
- 🇺🇸
University of Arizona College of Medicine, Tucson, Arizona, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸National Jewish Medical and Research Center, Denver, Colorado, United States
Inhaled Corticosteroids on Airway Smooth Muscle in Asthma
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- Imperial College London
- Registration Number
- NCT00661973
- Locations
- 🇬🇧
Asthma lab, Royal Brompton Hospital, Sydney Street, London, United Kingdom
Symbicort in Asthmatic Children - SEEDLING
- Conditions
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2009-03-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 405
- Registration Number
- NCT00651547
Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5
- Conditions
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT00652002
Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5
- Conditions
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT00651651
Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT
- Conditions
- Interventions
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 540
- Registration Number
- NCT00646321
Inhaled Steroid Treatment as Regular Therapy in Early Asthma
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6800
- Registration Number
- NCT00641914
Children, Perennial Allergic Rhinitis (PAR), l-t Growth
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 209
- Registration Number
- NCT00641212
Rhinocort Aqua Versus Placebo and Fluticasone Propionate
- Conditions
- Interventions
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 750
- Registration Number
- NCT00641680
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.